Increased risk of breast cancer-specific mortality among cancer survivors who developed breast cancer as a second malignancy.

Overall, patients with BCa-2 have worse breast cancer-specific survival, compared with their BCa-1 counterparts, although the risk elevation is mild. High-risk subgroups based on first malignancy's characteristics may be considered for active clinical management.